Skip to main content
HYUNDAI PHARMACEUTICAL CO., LTD logo

HYUNDAI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 004310 ISIN · KR7004310009 KO Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2018-10-31 Director's Dealing
Country KR South Korea
Listing KO 004310

About HYUNDAI PHARMACEUTICAL CO., LTD

http://www.hyundaipharm.co.kr/english

HYUNDAI PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, manufacturing, and distribution of pharmaceutical products, medical devices, and health-focused food and beverages. The company's portfolio encompasses a broad range of prescription (ETC) and over-the-counter (OTC) medicines. Key therapeutic areas include dermatology, respiratory and gastrointestinal disorders, as well as treatments for conditions such as hypertension and dementia. With a strong commitment to innovation, the company focuses on the research of new substances and the continuous development of its drug pipeline. It also serves as a strategic partner for global companies, facilitating market entry and collaboration through its business development initiatives.

Recent filings

Filing Released Lang Actions
최대주주등소유주식변동신고서
Director's Dealing Classification · 98% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Hyundai Pharm. It details specific changes in share ownership by major shareholders and executives (insiders), including transaction dates, types, and quantities. This falls under the category of 'Director's Dealing' (DIRS) as it reports insider share transactions, or alternatively 'Major Shareholding Notification' (MRQ). Given the focus on individual director/major shareholder transactions and their relationship to the company, DIRS is the most precise classification.
2018-10-31 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the change in shareholding percentage by a major shareholder (Lee Han-gu and special related parties) in Hyundai Pharm Co., Ltd. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels.
2018-10-31 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (DART system) to report insider trading or changes in shareholdings by company directors and major shareholders. Based on the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2018-10-31 Korean
분기보고서 (2018.08)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Hyundai Pharm Co., Ltd. (현대약품(주)) for the 3rd quarter of the 55th fiscal year (2017-12-01 to 2018-08-31). It contains detailed financial data, business operations, management discussion, and capital structure information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2018
2018-10-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.